Related Experiment Video
Updated: Jun 11, 2025
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Let's get functional: Drug sensitivity profiling to enable precision sarcoma medicine
Claudia R Ball1, Stefan Fröhling2
1Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT), NCT/University Cancer Center Dresden, a partnership between German Cancer Research Center (DKFZ), Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology (TUD), and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Dresden University of Technology (TUD), Dresden, Germany; Faculty of Biology, Dresden University of Technology (TUD), Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
Abstract:
Drug sensitivity profiling in patient-derived tumor models offers new hope for improving outcomes in cancers lacking effective therapies. Al Shihabi et al.1 demonstrate that short-term cultures from bone and soft tissue sarcomas enable clinically meaningful screening of multiple drugs and combinations, marking a significant advance in personalized care for these high-risk diseases.
Insights
Short-term cultures from patient tumors can screen multiple drugs for bone and soft tissue sarcomas. This advance offers personalized treatment options for high-risk cancer patients.
Area of Science:
- Oncology
- Translational Medicine
- Cancer Therapeutics
Background:
- Drug sensitivity profiling in patient-derived tumor models is crucial for cancers with limited treatment options.
- Bone and soft tissue sarcomas represent high-risk malignancies often lacking effective therapeutic strategies.
Purpose of the Study:
- To evaluate the utility of short-term cultures from bone and soft tissue sarcomas for drug sensitivity profiling.
- To determine if this approach enables clinically meaningful screening of drugs and drug combinations.
Main Methods:
- Establishment of short-term cultures from patient-derived bone and soft tissue sarcoma samples.
- Screening of multiple single-agent drugs and drug combinations for anti-cancer activity in these cultures.
Main Results:
- Short-term cultures successfully facilitated drug sensitivity profiling.
- The methodology allowed for clinically relevant screening of various therapeutic agents and combinations.
Conclusions:
- Short-term tumor cultures are a viable and effective tool for drug sensitivity screening in bone and soft tissue sarcomas.
- This approach represents a significant advancement in personalized cancer care for these challenging diseases.
